And they want to screen nearly everyone for Hep C?
Hepatitis C Drug's Price Draws Legislative Attention, Stock Analysts Sanguine — Physician’s First Watch
Hepatitis C Drug's Price Draws Legislative Attention, Stock Analysts Sanguine
By Joe Elia
Sovaldi (sofosbuvir), which received FDA approval last December to treat hepatitis C, costs an even $1000 per pill — or $84,000 for a 12-week course of treatment. That has legislators calling for the manufacturer to explain the price.
In a March 20 letter to Gilead Science's CEO, three members of the House Committee on Energy and Commerce write that, because hepatitis C is prevalent in low-income patients, "the affordability problems are likely to be particularly acute for state Medicaid programs and those patients served by these programs."
They request that Gilead explain how it arrived at the price, reminding the company of the value afforded by the FDA's priority review.
The New York Times reports that the letter sent Gilead's stock price down almost 5% on Friday. However, it quoted a Deutsche Bank analyst: "We just look at this letter as a little bit of noise."